GenSight raises €1.1 million ahead of RECOVER Phase 3
GenSight Biologics raised €1.1 million, generating about €1.05 million net, to fund operations through late March 2027 and prepare structural financing for RECOVER Phase 3.
Topic
Topic
GenSight Biologics raised €1.1 million, generating about €1.05 million net, to fund operations through late March 2027 and prepare structural financing for RECOVER Phase 3.